Virobay Facts

2014 – Virobay completes $8 million Series B preferred stock financing more

2014 – Virobay announces the appointment of James Welch as Chief Financial Officer more

2014 – Virobay appoints Thomas J. Dietz, Ph.D. to the Virobay Board of Directors more

2013 – Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain more

2013 – Virobay and LEO Pharma initiate a Phase 1 Trial of VBY-891, a compound intended for oral treatment of psoriasis more

more

Pipeline

Virobay is investigating promising new approaches for the treatment of neuroapathic pain, autoimmune diseases, liver fibrosis, and cancer.


Virobay Pipeline Table
 
Research
 
Phase 0
(Clinical Candidate)
 
Phase 1
 
Phase 2
VBY-891
Psoriasis - LEO Pharma     X  
VBY-036
Pain     X  
Crohn's Disease     X  
VBY-376
Fibrosis/NASH     X  
VBY-825
Fibrosis/PBC   X    
Multiple Candidates
Cancer, Alzheimer's X